IL1B and breast carcinoma: Current clinical trials are recruiting patients to investigate the safety and efficacy of the IL-1B antibody, Canakinumab, alongside immunotherapies such as the immune checkpoint inhibitors Spartalizumab and Pembrolizumab in breast cancer and other tumour types (ClinicalTrials.gov Identifier: NCT03484923, NCT03631199, NCT03968419, and NCT03742349).